Clinical Trials - May 15, 2015
Solid Tests for Smallpox Vaccine
Results of two pivotal Phase 3 studies of the liquid-frozen formulation of Bavarian Nordic A/S’s IMVAMUNE®, supporting a Biologics License Application for U.S. approval of the vaccine, were announced this week. In addition, the company announced results from a Phase 2 study of freeze-dried IMVAMUNE smallpox vaccine, supporting the clinical requirements for an Emergency Use […]